ANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a report released on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $80.00 target price on the specialty pharmaceutical company’s stock.

Several other analysts have also recently commented on ANIP. StockNews.com cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 3rd. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price target on the stock. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Guggenheim upped their price target on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Finally, Leerink Partners started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.75.

ANI Pharmaceuticals Stock Up 1.7 %

Shares of NASDAQ ANIP opened at $62.49 on Friday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $70.81. The firm has a 50-day moving average price of $58.40 and a 200 day moving average price of $58.06. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -113.62 and a beta of 0.62.

Insider Activity at ANI Pharmaceuticals

In related news, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $60.86, for a total transaction of $60,860.00. Following the transaction, the senior vice president now directly owns 66,525 shares in the company, valued at $4,048,711.50. The trade was a 1.48 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,700 shares of company stock valued at $610,201. Company insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Thrivent Financial for Lutherans increased its position in ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after purchasing an additional 299 shares during the last quarter. Exchange Traded Concepts LLC increased its position in shares of ANI Pharmaceuticals by 2.6% in the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock worth $684,000 after acquiring an additional 310 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of ANI Pharmaceuticals by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company’s stock worth $582,000 after acquiring an additional 364 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of ANI Pharmaceuticals by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock worth $246,000 after acquiring an additional 412 shares in the last quarter. Finally, Natixis Advisors LLC increased its position in shares of ANI Pharmaceuticals by 2.3% in the fourth quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company’s stock worth $1,028,000 after acquiring an additional 417 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.